Supplemental Submissions for PMAs and HDEs During COVID-19

by | Jun 17, 2020 | COVID-19, FDA, HDEs, Medical Devices, PMAs, Requirements

FDA has already issued temporary policies on how it regulates PPEs and various other covid-19 essential medical supplies during this public health emergency. On May 21,2020, FDA released another temporary policy that allows manufacturers of devices cleared under a Pre-Market Application or Humanitarian Device Exemptions to make changes to the product that would otherwise require a supplement or 30 day notice to be submitted to the FDA as long as the modification does not create undue risk.1

This policy provides manufacturers with the flexibility if they need to make a change due to the supply chain disruptions the industry is facing and continue their production without having to submit a supplement. Examples of modifications that are included in this policy are:1

  • Design and manufacturing changes to address component unavailability due to supply chain disruptions.
  • Manufacturing changes to allow the establishment to maintain operations and accommodate social distancing practices.
  • Changes in manufacturing facility or establishment to either increase the manufacturing capacity or shift to a manufacturing site that is not affected by Covid-19.
  • Changes to packaging procedures

This policy also applies to limited modifications to address current manufacturing limitations or supply chain issues due to COVID-19 that also result in changes to the performance or design specifications, circuits, components, ingredients, or physical layout of the device which would trigger the requirement to submit a 180-day or real-time PMA supplement or a 75-day HDE supplement.1

This policy does not cover any changes that are made to address manufacturing or supply chain issues not stemming from COVID-19 or changes that could add/create undue risk to the users of the device. Examples of such changes include:1

  • Changes to the intended use of the device, including new indications for use of the device
  • Changes to the labeling of the device, that are outside of the scope of recommendations described in other policies for specific devices during the public health emergency
  • Changes to the sterility assurance level (SAL) or sterilization method
  • Changes to reduce or eliminate quality control testing
  • Automation of a manufacturing process that is not fully verified
  • A change that affects the performance of the device, but is not caused by component unavailability

All changes that whether or not included in the scope of this policy must be performed in accordance with 21CFR820 and must be documented in the device master record and the change control record. Manufacturers must submit the records of such modifications whenever the next periodic report is due.1

Need help in bringing your medical device to the market. Call us today at 248-987-4497 or email us at

1FDA (May 2020) Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency retrieved from 05/26/2020 from

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This